Lumos Operating Income from 2010 to 2024

LUMO Stock

USD 4.30 0.01 0.23%

Lumos Pharma Operating Income yearly trend continues to be very stable with very little volatility. Operating Income is likely to drop to about -38.4 M. Operating Income is earnings before interest and taxes (EBIT), representing the amount of profit Lumos Pharma generates from its operations. View All Fundamentals

Operating Income

First Reported

2009-12-31

Previous Quarter

-7.8 M

Current Value

-7.6 M

Quarterly Volatility

21.9 M

Credit Downgrade

Yuan Drop

Covid

Check Lumos Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lumos Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 41.8 K, Interest Expense of 671.3 K or Selling General Administrative of 18.6 M, as well as many indicators such as Price To Sales Ratio of 12.0, Dividend Yield of 0.0 or PTB Ratio of 1.0. Lumos financial statements analysis is a perfect complement when working with Lumos Pharma Valuation or Volatility modules.

Check out the analysis of Lumos Pharma Correlation against competitors.

To learn how to invest in Lumos Stock, please use our How to Invest in Lumos Pharma guide.

Latest Lumos Pharma's Operating Income Growth Pattern

Below is the plot of the Operating Income of Lumos Pharma over the last few years. Operating Income is the amount of profit realized from Lumos Pharma operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Lumos Pharma is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Lumos Pharma's Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lumos Pharma's overall financial position and show how it may be relating to other accounts over time.

Operating Income

10 Years Trend

Pretty Stable

Compare to Others All Fundamentals

Operating Income

Timeline

Lumos Operating Income Regression Statistics

	Arithmetic Mean	(28,924,380)
	Geometric Mean	37,028,330
	Coefficient Of Variation	(158.25)
	Mean Deviation	24,687,453
	Median	(32,040,000)
	Standard Deviation	45,773,269
	Sample Variance	2095.2T
	Range	208.3M
	R-Value	(0.27)
	Mean Square Error	2086.8T
	R-Squared	0.08
	Significance	0.32
	Slope	(2,805,789)
	Total Sum of Squares	29332.7T

Lumos Operating Income History

	2024	-38.4 M
	2023	-36.6 M
	2022	-32 M
	2021	-31.3 M
	2020	-26.3 M
	2019	-45.1 M
	2018	-62.4 M

Other Fundumenentals of Lumos Pharma

Non Operating Income Net Other

Lumos Pharma Operating Income component correlations

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Short Term Investments	Net Tangible Assets	Long Term Debt	Long Term Debt Total	Capital Surpluse	Accumulated Depreciation	Property Plant Equipment	Deferred Long Term Liab	Treasury Stock	Short Long Term Debt	Net Invested Capital	Long Term Investments	Net Working Capital	Capital Stock
Total Assets		0.99	0.52	-0.99	-0.02	0.56	0.57	0.37	1.0	-0.23	0.58	0.23	0.93	-0.34	-0.36	0.54	-0.64	0.54	-0.03	0.13	0.21	0.39	0.35	0.4	0.28
Total Stockholder Equity	0.99		0.48	-0.99	-0.05	0.48	0.57	0.21	0.99	-0.19	0.57	0.22	0.92	-0.37	-0.4	0.54	-0.67	0.48	0.04	0.05	0.13	0.33	0.33	0.33	0.21
Current Deferred Revenue	0.52	0.48		-0.46	0.38	-0.03	0.39	0.38	0.52	-0.13	0.15	0.7	0.51	0.05	0.04	0.06	-0.15	0.53	-0.31	0.34	0.32	0.26	0.12	0.25	0.22
Net Debt	-0.99	-0.99	-0.46		0.1	-0.52	-0.51	-0.31	-0.99	0.24	-0.6	-0.17	-0.94	0.4	0.42	-0.61	0.69	-0.49	-0.06	-0.05	-0.13	-0.33	-0.32	-0.33	-0.26
Retained Earnings	-0.02	-0.05	0.38	0.1		-0.05	0.29	0.12	-0.03	0.13	-0.58	0.41	-0.01	0.44	0.45	-0.8	0.38	0.33	-0.57	0.51	0.45	0.32	0.11	0.33	-0.16
Accounts Payable	0.56	0.48	-0.03	-0.52	-0.05		0.13	0.6	0.55	-0.13	0.42	-0.17	0.48	-0.01	-0.03	0.28	-0.25	0.5	-0.36	0.4	0.47	0.42	0.18	0.41	0.37
Net Receivables	0.57	0.57	0.39	-0.51	0.29	0.13		0.17	0.58	-0.16	0.05	0.12	0.55	-0.22	-0.23	0.08	-0.35	0.14	0.06	-0.02	0.03	0.29	0.23	0.3	-0.1
Total Liab	0.37	0.21	0.38	-0.31	0.12	0.6	0.17		0.37	-0.3	0.19	0.12	0.39	0.04	0.04	0.21	-0.07	0.49	-0.4	0.43	0.47	0.38	0.07	0.38	0.44
Total Current Assets	1.0	0.99	0.52	-0.99	-0.03	0.55	0.58	0.37		-0.24	0.56	0.23	0.93	-0.37	-0.39	0.55	-0.67	0.51	0.0	0.09	0.18	0.37	0.34	0.37	0.25
Short Term Debt	-0.23	-0.19	-0.13	0.24	0.13	-0.13	-0.16	-0.3	-0.24		-0.03	-0.02	-0.3	0.24	0.27	-0.3	0.39	0.0	-0.19	0.17	0.15	0.1	0.06	0.1	0.1
Common Stock	0.58	0.57	0.15	-0.6	-0.58	0.42	0.05	0.19	0.56	-0.03		-0.14	0.42	0.03	0.01	0.72	-0.19	0.53	-0.06	0.22	0.32	0.48	0.41	0.47	0.77
Short Term Investments	0.23	0.22	0.7	-0.17	0.41	-0.17	0.12	0.12	0.23	-0.02	-0.14		0.19	0.0	-0.01	-0.18	-0.11	0.23	-0.17	0.14	0.12	-0.01	0.13	-0.01	-0.08
Net Tangible Assets	0.93	0.92	0.51	-0.94	-0.01	0.48	0.55	0.39	0.93	-0.3	0.42	0.19		-0.47	-0.49	0.58	-0.72	0.43	0.05	0.02	0.07	0.18	0.03	0.18	0.13
Long Term Debt	-0.34	-0.37	0.05	0.4	0.44	-0.01	-0.22	0.04	-0.37	0.24	0.03	0.0	-0.47		1.0	-0.59	0.91	0.55	-0.8	0.83	0.8	0.64	0.3	0.63	0.56
Long Term Debt Total	-0.36	-0.4	0.04	0.42	0.45	-0.03	-0.23	0.04	-0.39	0.27	0.01	-0.01	-0.49	1.0		-0.61	0.93	0.54	-0.79	0.82	0.79	0.63	0.29	0.63	0.55
Capital Surpluse	0.54	0.54	0.06	-0.61	-0.8	0.28	0.08	0.21	0.55	-0.3	0.72	-0.18	0.58	-0.59	-0.61		-0.68	0.02	0.44	-0.36	-0.29	-0.13	-0.08	-0.13	0.27
Accumulated Depreciation	-0.64	-0.67	-0.15	0.69	0.38	-0.25	-0.35	-0.07	-0.67	0.39	-0.19	-0.11	-0.72	0.91	0.93	-0.68		0.24	-0.59	0.62	0.57	0.4	0.13	0.39	0.37
Property Plant Equipment	0.54	0.48	0.53	-0.49	0.33	0.5	0.14	0.49	0.51	0.0	0.53	0.23	0.43	0.55	0.54	0.02	0.24		-0.75	0.87	0.9	0.82	0.43	0.81	0.79
Deferred Long Term Liab	-0.03	0.04	-0.31	-0.06	-0.57	-0.36	0.06	-0.4	0.0	-0.19	-0.06	-0.17	0.05	-0.8	-0.79	0.44	-0.59	-0.75		-0.91	-0.88	-0.64	-0.19	-0.63	-0.57
Treasury Stock	0.13	0.05	0.34	-0.05	0.51	0.4	-0.02	0.43	0.09	0.17	0.22	0.14	0.02	0.83	0.82	-0.36	0.62	0.87	-0.91		0.98	0.77	0.3	0.76	0.7
Short Long Term Debt	0.21	0.13	0.32	-0.13	0.45	0.47	0.03	0.47	0.18	0.15	0.32	0.12	0.07	0.8	0.79	-0.29	0.57	0.9	-0.88	0.98		0.86	0.41	0.85	0.76
Net Invested Capital	0.39	0.33	0.26	-0.33	0.32	0.42	0.29	0.38	0.37	0.1	0.48	-0.01	0.18	0.64	0.63	-0.13	0.4	0.82	-0.64	0.77	0.86		0.71	1.0	0.76
Long Term Investments	0.35	0.33	0.12	-0.32	0.11	0.18	0.23	0.07	0.34	0.06	0.41	0.13	0.03	0.3	0.29	-0.08	0.13	0.43	-0.19	0.3	0.41	0.71		0.72	0.44
Net Working Capital	0.4	0.33	0.25	-0.33	0.33	0.41	0.3	0.38	0.37	0.1	0.47	-0.01	0.18	0.63	0.63	-0.13	0.39	0.81	-0.63	0.76	0.85	1.0	0.72		0.75
Capital Stock	0.28	0.21	0.22	-0.26	-0.16	0.37	-0.1	0.44	0.25	0.1	0.77	-0.08	0.13	0.56	0.55	0.27	0.37	0.79	-0.57	0.7	0.76	0.76	0.44	0.75

Click cells to compare fundamentals

About Lumos Pharma Financial Statements

Lumos Pharma investors utilize fundamental indicators, such as Operating Income, to predict how Lumos Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.

	Last Reported	Projected for Next Year
Operating Income	-36.6 M	-38.4 M
Non Operating Income Net Other	7.7 M	8.1 M

When determining whether Lumos Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lumos Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lumos Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lumos Pharma Stock:

How To Invest In Lumos

Details

Is Lumos Stock a good investment?

Details

What is Lumos Pharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Lumos Pharma Correlation against competitors.

To learn how to invest in Lumos Stock, please use our How to Invest in Lumos Pharma guide.

You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lumos Pharma. If investors know Lumos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lumos Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(4.28)

Revenue Per Share

0.27

Quarterly Revenue Growth

102.714

Return On Assets

(0.70)

Return On Equity

(1.73)

The market value of Lumos Pharma is measured differently than its book value, which is the value of Lumos that is recorded on the company's balance sheet. Investors also form their own opinion of Lumos Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lumos Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lumos Pharma's market value can be influenced by many factors that don't directly affect Lumos Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Lumos Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lumos Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lumos Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Lumos Operating Income from 2010 to 2024

Latest Lumos Pharma's Operating Income Growth Pattern

Lumos Operating Income Regression Statistics

Lumos Operating Income History

Other Fundumenentals of Lumos Pharma

Lumos Pharma Operating Income component correlations

About Lumos Pharma Financial Statements

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY